Prudential plc
NYSE:PUKInsurance - Life
+$0.02 today
- Market cap
- $30.44B
- Beta
- 0.91
- P/E (TTM)
- 9.3
- EPS (TTM)
- $1.44
- Dividend yield
- 0.02%
Volume 1.21M
Average 1.09M
PUK Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Prudential plcNYSE: PUK
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures declines year over year
Q2 FY2026 capital expenditures of $20M (cash outflow) fell 57.8% year over year. Over 3 fiscal years it compounded at +45.2% a year.
Context
- Capital expenditures amounted to 0.4% of revenue in FY2025, down 0.9 pp from a year earlier.
- Capital expenditures grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (104.1M) USD
- Year-over-year change
- -3.1%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (104.1M) | -3.1% |
| FY2024 | 2024-12-31 | (101M) | -129.5% |
| FY2023 | 2023-12-31 | (44M) | -29.5% |
| FY2022 | 2022-12-31 | (33.98M) | +5.6% |
| FY2021 | 2021-12-31 | (36M) | — |
Capital Expenditures vs competitors
How PUK compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Capital expenditures amounts to 0.4% of revenue for PUK, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | $104.1M USD | +3.1% | +45.2% | 0.4% | |
| LTM Jun 2026 | CA$0 CAD | — | — | 0.0% | |
| LTM Jun 2026 | $0 USD | — | — | 0.0% | |
| LTM Jun 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding PUK) | — | — | — | 0.0% | |
Competitors are the stored peer set for PUK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 3.02B | (833.01M) | 2.27B | 3.24B | 3.98B |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 73.95M | 0 | 0 | 0 | 0 |
| Change in Working Capital | (5.44B) | (20.44B) | 12.79B | 206.09M | (1.35B) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | (5.44B) | (20.44B) | 12.79B | 206.09M | (1.35B) |
| Other Non-Cash Items | 2.63B | 22.35B | (14.23B) | 163.91M | (360.34M) |
| Operating Cash Flow | 278M | 873.46M | 832M | 3.61B | 2.28B |
| Capital Expenditures | (36M) | (33.98M) | (44M) | (101M) | (104.1M) |
| Acquisitions (Net) | (690M) | (5M) | (142M) | (557M) | 1.19B |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (6.4M) | (174M) | (174M) | 4M |
| Investing Cash Flow | (726M) | (39M) | (360M) | (832M) | 1.09B |
| Debt Repayment | (275.82M) | (1.73B) | (393M) | (92.94M) | 462.43M |
| Common Stock Issued | 2.38B | 0 | 4M | 0 | 2M |
| Common Stock Repurchased | 0 | (4M) | 0 | (860M) | (1.25B) |
| Dividends Paid | (421M) | (474M) | (533M) | (552M) | (594.56M) |
| Other Financing Activities | (420.18M) | (313M) | (288M) | (190.06M) | (186.17M) |
| Financing Cash Flow | 1.27B | (2.52B) | (1.21B) | (1.7B) | (1.57B) |
| Effect of Forex Changes | (44M) | (175M) | (25M) | (61M) | 135.62M |
| Net Change in Cash | 773M | (1.66B) | (763M) | 1.02B | 1.93B |
| Free Cash Flow | 242M | 839.48M | 788M | 3.51B | 2.17B |
Prudential plc
NYSE:PUK
Intrinsic Alpha fair value
Locked
Current Price
$24.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.